A Retrospective Cohort Study Evaluating the Safety and Efficacy of Sequential versus Concurrent Intrapleural Instillation of Tissue Plasminogen Activator and DNase for Pleural Infection

IF 2 Q3 RESPIRATORY SYSTEM Pulmonary Medicine Pub Date : 2023-12-18 DOI:10.1155/2023/6340851
K. Goh, Wui Mei Chew, J. Ong, C. Leong, Imran Bin Mohamed Noor, D. Anantham, Li Yan Sandra Hui, Mindy Chu Ming Choong, Charlene Jin Yee Liew, Marnie Tamayo Gutierrez, Jane Wong, Ivana Phua, Wen Ting Lim, Qiao Li Tan
{"title":"A Retrospective Cohort Study Evaluating the Safety and Efficacy of Sequential versus Concurrent Intrapleural Instillation of Tissue Plasminogen Activator and DNase for Pleural Infection","authors":"K. Goh, Wui Mei Chew, J. Ong, C. Leong, Imran Bin Mohamed Noor, D. Anantham, Li Yan Sandra Hui, Mindy Chu Ming Choong, Charlene Jin Yee Liew, Marnie Tamayo Gutierrez, Jane Wong, Ivana Phua, Wen Ting Lim, Qiao Li Tan","doi":"10.1155/2023/6340851","DOIUrl":null,"url":null,"abstract":"Background and Objective. Intrapleural tissue plasminogen activator/deoxyribonuclease (tPA/DNase) is increasingly being used for pleural infections. Compared to sequential instillation of tPA/DNase, concurrent instillation considerably reduces the complexity of the administration process and reduces workload and the number of times the chest drain is accessed. However, it remains unclear if concurrent intrapleural therapy is as efficacious or safe as sequential intrapleural therapy. Methods. We conducted a retrospective review of patients with pleural infection requiring intrapleural therapy at two tertiary referral centres. Results. We included 84 (62.2%) and 51 (37.8%) patients who received sequential and concurrent intrapleural therapy, respectively. Patient demographics and clinical characteristics, including age, RAPID score, and percentage of pleural opacity on radiographs before intrapleural therapy, were similar in both groups. Treatment failure rates (defined by either in-hospital mortality, surgical intervention, or 30-day readmission for pleural infection) were 9.5% and 5.9% with sequential and concurrent intrapleural therapy, respectively (\n \n p\n =\n 0.534\n \n ). This translates to a treatment success rate of 90.5% and 94.1% for sequential and concurrent intrapleural therapy, respectively. There was no significant difference in the decrease in percentage of pleural effusion size on chest radiographs (15.1% [IQR 6-35.7] versus 26.6% [IQR 9.9-38.7], \n \n p\n =\n 0.143\n \n ) between sequential and concurrent therapy, respectively. There were also no significant differences in the rate of pleural bleeding (4.8% versus 9.8%, \n \n p\n =\n 0.298\n \n ) and chest pain (13.1% versus 9.8%, \n \n p\n =\n 0.566\n \n ) between sequential and concurrent therapy, respectively. Conclusion. Our study adds to the growing literature on the safety and efficacy of concurrent intrapleural therapy in pleural infection.","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/6340851","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Objective. Intrapleural tissue plasminogen activator/deoxyribonuclease (tPA/DNase) is increasingly being used for pleural infections. Compared to sequential instillation of tPA/DNase, concurrent instillation considerably reduces the complexity of the administration process and reduces workload and the number of times the chest drain is accessed. However, it remains unclear if concurrent intrapleural therapy is as efficacious or safe as sequential intrapleural therapy. Methods. We conducted a retrospective review of patients with pleural infection requiring intrapleural therapy at two tertiary referral centres. Results. We included 84 (62.2%) and 51 (37.8%) patients who received sequential and concurrent intrapleural therapy, respectively. Patient demographics and clinical characteristics, including age, RAPID score, and percentage of pleural opacity on radiographs before intrapleural therapy, were similar in both groups. Treatment failure rates (defined by either in-hospital mortality, surgical intervention, or 30-day readmission for pleural infection) were 9.5% and 5.9% with sequential and concurrent intrapleural therapy, respectively ( p = 0.534 ). This translates to a treatment success rate of 90.5% and 94.1% for sequential and concurrent intrapleural therapy, respectively. There was no significant difference in the decrease in percentage of pleural effusion size on chest radiographs (15.1% [IQR 6-35.7] versus 26.6% [IQR 9.9-38.7], p = 0.143 ) between sequential and concurrent therapy, respectively. There were also no significant differences in the rate of pleural bleeding (4.8% versus 9.8%, p = 0.298 ) and chest pain (13.1% versus 9.8%, p = 0.566 ) between sequential and concurrent therapy, respectively. Conclusion. Our study adds to the growing literature on the safety and efficacy of concurrent intrapleural therapy in pleural infection.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一项回顾性队列研究,评估胸膜腔内同时灌注组织浆细胞酶原激活剂和 DNase 治疗胸膜感染的安全性和有效性
背景和目的。胸膜腔内组织纤溶酶原激活剂/脱氧核糖核酸酶(tPA/DNase)越来越多地被用于治疗胸膜感染。与连续灌注 tPA/DNase 相比,同时灌注大大降低了给药过程的复杂性,减少了工作量和胸腔引流管的使用次数。然而,目前还不清楚同期胸膜腔内治疗是否与顺序胸膜腔内治疗一样有效或安全。方法。我们对两家三级转诊中心需要胸膜腔内治疗的胸膜感染患者进行了回顾性研究。结果我们分别纳入了 84 例(62.2%)和 51 例(37.8%)接受序贯胸膜腔内治疗和同期胸膜腔内治疗的患者。两组患者的人口统计学和临床特征(包括年龄、RAPID评分和胸膜腔内治疗前X光片上胸膜不透明的百分比)相似。治疗失败率(定义为院内死亡、手术干预或因胸膜感染而再次入院 30 天)在连续胸膜腔内治疗和同期胸膜腔内治疗中分别为 9.5% 和 5.9% (P = 0.534)。这意味着序贯胸膜腔内疗法和同期胸膜腔内疗法的治疗成功率分别为 90.5% 和 94.1%。序贯疗法和并发疗法在胸片上胸腔积液面积减少的百分比上没有明显差异(15.1% [IQR 6-35.7] 对 26.6% [IQR 9.9-38.7],p = 0.143)。在胸膜出血率(4.8% 对 9.8%,P = 0.298)和胸痛率(13.1% 对 9.8%,P = 0.566)方面,序贯疗法和同期疗法也分别没有明显差异。结论我们的研究为越来越多有关胸膜腔内同时治疗胸膜感染的安全性和有效性的文献增添了新的内容。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pulmonary Medicine
Pulmonary Medicine RESPIRATORY SYSTEM-
CiteScore
10.20
自引率
0.00%
发文量
4
审稿时长
14 weeks
期刊最新文献
Practice Variations in the Diagnosis and Treatment of Pulmonary Embolism. The Impact of COVID-19 Pandemic on Respiratory Syncytial Virus Infection in Children. Dual-Task Performance in Individuals With Chronic Obstructive Pulmonary Disease: A Systematic Review With Meta-Analysis. Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Adherence to the ISHLT Protocol for the Referral of Patients with Idiopathic Pulmonary Fibrosis to the Transplantation Center among of Czech Centers for Interstitial Lung Diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1